The full name of car-t cell therapy is chimeric antigen receptor T-cell therapy, and the main indication at present is hematologic malignancies.
Car-t cell therapy is a new treatment for malignant tumors, belonging to a kind of immunotherapy, and the car-t cell therapy that has been approved for marketing is mainly applied to certain refractory hematologic malignant tumors.
For example, the approved indications for the first car-t therapy, Akirensai Injection, which has been approved for marketing in China, are for adult patients with relapsed or refractory large b-cell lymphoma who have previously received more than second-line systemic therapy. In addition to Argirenzide injection, a variety of similar therapies have been approved and marketed abroad, but the main indications are hematologic malignancies.
Although there have been many studies related to the application of car-t cell therapy to solid tumors in the medical community, none of them has achieved clear efficacy, and no related therapies have been approved and marketed. However, car-t therapy applied to solid tumors has a wide range of research prospects, and it is believed that there will be relevant breakthroughs in the near future, which will bring the gospel to patients with solid tumors.
There are clear indications and contraindications for car-t cell therapy, and it is currently expensive and not applicable to other malignant tumors. It is recommended that patients go to the hospital as early as possible and ask professional doctors to evaluate and decide whether to use it.